Investor Relations

TScan is dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system.

Corporate Profile

TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiple TCR-T therapy candidates for the treatment of various solid tumors.

Stock Information

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

10 Jan '22
IND Submissions Completed in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Candidates TSC-100 and TSC-101 Lead TCR Identified for Solid Tumor Program Targeting HPV16; Further TCRs Advancing into IND-Enabling Activities with IND Submissions Planned for Second Half of 2022 TScan Developing...

Latest Presentations

SEC Filings

Filing date Description Form

Notice of Exempt Offering of Securities


Notice of Exempt Offering of Securities


Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy